Clinical Trial Update: Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial called CLASP evaluating a cholesterol-lowering agent for slowing progression of Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Cholesterol Lowering Agent

Snippet

Sponsor: National Institute on Aging (NIA) | Conditions: Alzheimer Disease | Phase 3 | Status: COMPLETED